{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-036285","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.557954+00:00","generated_at":"2026-06-19T14:17:39.089071+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026","bullets":["Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.","CLN-418/HBM7008 is a clinical-stage (Phase 1) B7H4 x 4-1BB bispecific immune activator for solid tumors.","Cash and investments $550M at end 2022; after $25M upfront would be $525M; expects cash to last into 2026.","Company expects to have six clinical-stage assets in pipeline by end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-036285","json":"https://secwatch.observer/filing/0001193125-23-036285.json","markdown":"https://secwatch.observer/filing/0001193125-23-036285.md","text":"https://secwatch.observer/filing/0001193125-23-036285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/0001193125-23-036285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/d436936d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:17:39.089071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"290f62609e2d6fa089eeb86fa7c655bd23cd039a","claim":"Cullinan Therapeutics, Inc. entered into License Agreement with Harbour BioMed US Inc. valued at $25 million upfront license fee (effective 2023-02-13).","evidence_excerpt":"On February 13, 2023, Cullinan Oncology, Inc. (the \"Company\") and Harbour BioMed US Inc. (\"Harbour\") entered into a License and Collaboration Agreement (the \"License Agreement\"), pursuant to which Harbour granted to the Company an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/0001193125-23-036285-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Harbour BioMed US Inc."},{"label":"Value","value":"$25 million upfront license fee"},{"label":"Effective","value":"2023-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}